IOVA logo

IOVA Iovance Biotherapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$6.90
-0.41 (-5.61%)

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, eva…

Market Cap: $3.19Bwww.iovance.com

Price

No data yet.

Social Signal Score

55
5d
—
30d
55
16 mentions
—
60d
55
28 mentions
—
90d
55
30 mentions
—
news: 22 · rss: 6 · marketaux: 2

Analyst Ratings

21 analysts
Buyconsensus
Strong Buy 0Buy 15Hold 6Sell 0Strong Sell 0
Avg price target$13.56+96.5%
Low $5Median $15High $20
Current Consensus

Revenue

$121.47M
$0.00$40.49M$80.98M$121.47M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.08
$-1.13–$-1.01
6 analysts
FY2026
$-0.38
$-0.51–$-0.28
6 analysts
FY2027
$-0.09
$-0.21–$-0.03
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Frederick G. Vogt
Sector
Healthcare
Industry
Biotechnology
Employees
975
Beta
0.76
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
6.76
www.iovance.com